Patient-Specific Therapeutic Vaccines for Metastatic Melanoma

Click to increase image sizeClick to decrease image size

Additional information

Notes on contributors

Robert O. Dillman

Robert O. Dillman, MD, is vice president of Oncology, NeoStem, Inc., and clinical professor of Medicine, University of California Irvine. Dr. Dillman became vice-president of Oncology for NeoStem, Inc., in May 2014 when it acquired California Stem Cell, Inc., where he was chief medical officer from 2012–2014. During 2011–2014 he also served as executive medical director of the Hoag Hospital Institute for Research and Education, in Newport Beach, Calif. Prior to that, Dr. Dillman was executive medical director of the Hoag Family Cancer Institute (2008–2011), and medical director of the Hoag Cancer Center (1989–2008) where he directed the translational cell biology research laboratory focused on bench-to-bedside patient-specific cell therapies, which was acquired by California Stem Cell in 2011.